Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 = 50%
- Conditions
- Advanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-503221-19-00
- Lead Sponsor
- Regeneron Pharmaceuticals Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Participants with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic) disease who received no prior systemic treatment for recurrent or metastatic NSCLC, Availability of an archival or on-study obtained formalin-fixed, paraffin-embedded tumor tissue sample as defined in the protocol., Expression of Programmed cell death ligand-1 (PD-L1) in =50% of tumor cells stained using the VENTANA PD-L1 (SP263) Assay as performed by a central laboratory, Participants must have at least 1 radiographically measurable lesion by computerized tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria, Eastern Cooperative Oncology Group (ECOG) performance status =1, Other protocol-defined inclusion criteria apply
Participants who have never smoked, defined as smoking =100 cigarettes in a lifetime, Another malignancy that is progressing or requires treatment, with the exception of non-melanomatous skin cancer that has undergone potentially curative therapy, in situ cervical carcinoma, or any other localized tumor that has been treated, and the participant is deemed to be in complete remission for at least 2 years prior to enrollment, and no additional therapy is required during the study period, Documented or suspected ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as defined in the protocol, Patients who have received prior systemic therapies for NSCLC are excluded with the exception of the following:Adjuvant or neoadjuvant platinum-based doublet chemotherapy (after surgery and/or radiation therapy) if recurrent or metastatic disease develops more than 6 months after completing therapy as long as toxicities have resolved to CTCAE grade =1 or baseline with the exception of alopecia and peripheral neuropathy., Patients who have received prior systemic therapies for NSCLC are excluded with the exception of the following:Anti-PD-(L)1 with or without LAG-3 as an adjuvant or neoadjuvant therapy as long as the last dose is >12 months prior to enrollment., Patients who have received prior systemic therapies for NSCLC are excluded with the exception of the following:Prior exposure to other immunomodulatory or vaccine therapies as an adjuvant or neoadjuvant therapy such as anti-cytotoxic T lymphocyte-associated antigen (anti-CTLA-4) antibodies as long as the last dose is >6 months prior to enrollment, History or current evidence of significant cardiovascular disease including, myocarditis, congestive heart failure (as defined by New York Heart Association Functional Classification III and IV), unstable angina, serious uncontrolled arrhythmia, and myocardial infarction 6 months prior to study enrollment., Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling., Other protocol-defined Exclusion criteria apply, Active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment, Participants with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene receptor tyrosine kinase 1 (ROS1) fusions, Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment, Participants with history of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years, Prior splenectomy, Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol, Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-related treatment-emergent adverse events (imTEAEs), Participants requiring corticosteroid therapy (>5 mg prednisone/da
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To assess the objective response rate (ORR) per blinded independent review committee (BIRC) of combination of cemiplimab and BNT116 and cemiplimab monotherapy in the first-line treatment of patients with advanced NSCLC whose tumors express PD-L1 in =50% of tumor cells.;Secondary Objective: To assess other anti-tumor activities of combination of cemiplimab and BNT116 and cemiplimab monotherapy, as measured by ORR per investigator assessment, DOR, PFS, and OS., To further examine the safety and tolerability of combination of cemiplimab and BNT116 and cemiplimab monotherapy.;Primary end point(s): Objective response rate (ORR) as assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
- Secondary Outcome Measures
Name Time Method Secondary end point(s):ORR by investigator assessment;Secondary end point(s):Duration of Response (DOR) as assessed by BIRC using RECIST 1.1;Secondary end point(s):DOR by investigator assessment;Secondary end point(s):Progression Free Survival (PFS) as assessed by BIRC using RECIST 1.1;Secondary end point(s):PFS by investigator assessment;Secondary end point(s):Overall Survival (OS);Secondary end point(s):Incidence of treatment-emergent adverse events (TEAEs);Secondary end point(s):Incidences of serious adverse events (SAEs);Secondary end point(s):Incidences of deaths;Secondary end point(s):Incidences of Grade 3-4 laboratory abnormalities